系统性硬化症相关间质性肺病高分辨率CT演变:描述与预后因素
该研究纳入58例系统性硬化症相关间质性肺病(SSc-ILD)患者,纵向收集高分辨率CT(HRCT)和肺功能检查(PFT),采用线性混合模型分析ILD范围演变。结果显示ILD范围年均进展0.92±0.36%(p=0.018),男性、弥漫性皮肤型SSc、抗拓扑异构酶1抗体阳性及基线较轻ILD与更快进展相关;DLCO下降与ILD范围进展显著相关,基线及随访ILD范围与生存相关。
要点
- SSc-ILD患者HRCT上ILD范围年均进展0.92±0.36%(p=0.018)。
- 男性、dcSSc、抗拓扑异构酶1抗体阳性及基线较轻ILD与更快进展相关。
- DLCO下降与HRCT上ILD范围进展显著相关,FVC仅呈趋势。
核心结论
- 男性、弥漫性皮肤型SSc、抗拓扑异构酶1抗体阳性及基线ILD较轻与ILD范围更快进展相关。
- DLCO演变与HRCT上ILD范围变化显著相关,基线及随访ILD范围与生存相关。
研究设计与样本
- 研究纳入58例SSc-ILD患者,收集所有可用的HRCT和PFT,采用线性混合模型(随机效应)建模PFT和HRCT演变。
主要发现
- 患者平均随访5.3±4.9年,中位HRCT扫描3次(总n=203),中位PFT 5次(总n=329)。
- ILD诊断时平均SSc病程2.5±3.1年,基线平均ILD范围32.3±28.7%。
- HRCT上ILD范围年均进展0.92±0.36%(p=0.018)。
- 双变量分析中男性、dcSSc、抗拓扑异构酶1抗体阳性、较高DLCO、局限型ILD及低coarseness评分与更快进展相关;多变量分析中抗拓扑异构酶1抗体阳性和coarseness评分为0与更快进展相关。
- ILD范围进展与DLCO下降显著相关,与FVC下降仅呈趋势;基线及随访ILD范围与生存相关。
关键数值与推荐
- 基线平均ILD范围32.3±28.7%,年均进展0.92±0.36%(p=0.018)。
临床怎么用
- 对于男性、dcSSc、抗拓扑异构酶1抗体阳性或基线ILD较轻的SSc-ILD患者,应警惕HRCT上ILD范围更快进展。
- 随访中DLCO下降可能提示HRCT上ILD范围进展,需结合HRCT评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aims of our study were to describe the evolution of interstitial lung disease (ILD) extent on HRCT scan in systemic sclerosis (SSc), to identify baseline prognostic factors associated with ILD evolution and to assess whether the evolution of pulmonary function tests (PFTs) correlated with this evolution. METHODS: 58 SSc with ILD (SSc-ILD) patients were included. All HRCT scans and PFTs available were collected. We modelized PFTs and HRCT scans evolution using linear mixed model with random effect. RESULTS: Patients underwent a median number of 3 HRCT scans (total n = 203) and 5 PFTs (total n = 329), during a mean follow-up of 5.3 ± 4.9 years. Mean SSc duration was 2.5 ± 3.1 years at the diagnosis of ILD. Mean baseline ILD extent was 32.3 ± 28.7%. We found a significant mean progression of ILD extent on serial HRCT scans of 0.92 ± 0.36% per year (p = 0.018). Male sex, diffuse cutaneous SSc (dcSSc), presence of anti-topoisomerase 1 antibodies, a higher DLCO, limited ILD and a low coarseness score at baseline in bivariate analysis, and presence of antitopoisomerase 1 antibodies and a coarseness score of 0 in multivariate analysis, were associated with faster progression of ILD extent over time There was a significant correlation between the progression of ILD extent and the decline of DLCO but only a trend for FVC. ILD extent at baseline and during follow-up was associated with survival. CONCLUSION: Male sex, dcSSc, anti-topoisomerase 1 antibodies and a less severe ILD at baseline were associated with a faster progression of ILD over time. Evolution of DLCO significantly correlated with change in ILD extent on HRCT scan. Our study helps defining the profile of patients at risk of experiencing a progression of ILD on HRCT scans.
引用
- Forestier A, Le Gouellec N, Béhal H, et al. Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. Semin Arthritis Rheum. 2020. PMID: 32245698. doi:10.1016/j.semarthrit.2020.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。